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Artigo / Article
Maturation of dendritic cells following exposure to different maturational stimuli





Dendritic cells (DCs) are professional antigen-presenting cells that are highly effective
to immunize against pathogens and tumor antigens. In order to obtain mature DCs
several in vitro methods have been reported. Selecting the most efficient and effective
method of generating morphologic and phenotypic DCs within 7 days of culture is an
essential prerequisite for success in immunotherapy strategies. Herein, we report a
method of obtaining an enriched monocyte population from blood donors and
performed a comparison of DC maturation in response to four agents. Monocyte
populations with 91% ± 5 of purity were obtained from 15 healthy donors. The resulting
monocyte populations were cultured in the presence of GM-CSF and IL-4 during 5
days. At day 5 different maturation conditions were performed and morphological
and phenotypical changes were analyzed. Our study demonstrates that TNF-α or
PGE1 by themselves can induce the expression of CD1a 2.4 and 2.7 times respectively
more than DC cultures in the absence of maturing agents. On the other hand, for
other costimulatory or accessory molecules (CD80, CD86, CD83 and CD40) TNF-α
was more potent in the induction of expression than PGE1, although in the presence
of TNF-α plus PGE1 this effect is more pronounced compared to TNF-α alone. Under
TNF-α plus PGE1 treatment the phenotypical maturation of immature DCs are
comparable to LPS and therefore TNF-α+ PGE1 might be useful for generating ex-
vivo DCs to use in protocols of cell vaccination. Further functional evaluation of
these mature DCs is warranted.  Rev. bras. hematol. hemoter. 2006;28(2):89-96.
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Introduction
Dendritic cells (DCs), which were discovered more
than 25 years ago, are the most potent members in the class
of antigen-presenting cells (APCs) and are initiators and
modulators of the immune response. They are mobile
sentinels that bring antigens to T-cells and express co-
stimulators for the induction of immunity.1,2  The exceptional
ability of DCs to stimulate T-cells in vivo is attributed to
their dichotomous nature, as immature and mature DCs.
Immature DCs (iDCs), exist in peripheral tissues, where
they continuously capture and process antigens, but they
are relatively poor stimulators of T-cell responses. Upon
exposure to inflammatory cytokines, iDCs upregulate
costimulatory molecules and chemokine receptors. The first
are required for the activation of antigen-specific T-cells,
which takes place in the T-cell region of draining lymph
nodes and the second are required for their migration to the
lymph nodes. The mature dendritic cells (mDC) express a
unique repertoire of cell-surface molecules including high
levels of: a) molecules involved in antigen presentation to
T-cells, such as, MHC class I, MHC class II and CD1a; b)
adhesion molecules, such as, ICAM-1 (CD54), LFA-3
(CD58), Mac-1a (CD11c), SIRP-1a (CD172), VLA-4a
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(CD49d) and VLA-5a (CD49e); c) costimulatory and
accessory molecules, for example, B7-1 (CD80), B7-2
(CD86), CD40 and CD83 and d) chemokines receptors, such
as, CCR7 and CXCR4.3,4
The key role of DCs in the initiation of immune
responses has focused the attention of many investigators
on the potential efficacy of these cells in tumor immuno-
therapy,5,6 for antiviral CTL responses7 and for anti-
infection response for common intracellular pathogens
such as leishmaniasis, histoplasmosis and mycobacterial
species.8-10
The focus of our laboratory is to develop a very efficient
and effective method of generating morphologic and
phenotypic DCs within short periods to allow their use in
cancer immunotherapy.
In developing strategies to optimize the use of dendritic
cell-based immunotherapy in humans, several experimen-
tal methods have been reported.11-13 At present, most of the
clinical trials use DCs generated from monocytes based on
the findings of Sallusto and Lanzavechhia,14 which consist
in the generation of mature DCs by culturing peripheral
blood mononuclear cells in the presence of GM-CSF plus
interleukin 4 (IL-4) for one week followed by stimulation
with TNF-α for 48h. GM-CSF is a growth factor for stem
cells from granulocyte and macrophage lineages15 and in
DC cultures it appears to increase the expression of class II
major histocompatibility complex (MHC) antigens,
enhancing the antigen presenting capacity of DCs. IL-4
inhibits both granulocyte and macrophage development and
it seems to keep DCs in an "immature" state, thus more
capable of processing exogenous antigens. TNF-α in DC
cultures appears to inhibit the granulocyte maturation and
promotes the maturation of DCs to a state where they lose
their ability to process antigens but are very active in
stimulating naive lymphocytes.
As maturation is an essential part of DC function
increasing effort has been devoted to study other maturation
stimuli. Some other DC maturation stimuli include microbial
products (e.g., lipopolysaccharide  LPS,16-17), prostaglandin
E (PGE,18-19), CD40 ligand20 and several combinations of
these molecules have been used for ex vivo generation of
mature DCs.13,21-23
It is well-established in these studies that exogenous
prostaglandins E2 or E1 can enhance the TNF-α -induced
maturation in DCs as analysed by morphology, phenotype,
ability to stimulate the allogeneic mixed leukocyte
reaction, and induction of IL-12 production,13,19,24 but a
systematic comparison of the phenotypical maturation of
DCs generated from normal volunteers has not been
performed yet.
In this study we performed a comparative study among
four different DC maturation agents to investigate the
influence of proinflammatory factors (TNF-α and PGE1) in
isolation or TNF-α in combination with PGE1, as well as
bacterial products (LPS) in the expression of each molecule
characteristic of mature DCs, including CD1a, CD80, CD86,
CD83 and CD40 evaluated by flow cytometry. Also, the
characteristics of DCs were determined by evaluating their
morphology by light microscopy. Our study demonstrates
that TNF-α or PGE1 by itself can increase the CD1a
expression by 2.4 and 2.7 times, respectively, more than
DC cultures in the absence of maturing agents. On the other
hand, for other costimulatory or accessory molecules (CD80,
CD86, CD83 and CD40) TNF-α  was more potent to induce
the expression compared to PGE1, although in the presence
of TNF-α plus PGE1 this effect is more pronounced compared
to TNF-α alone. Under TNF-α plus PGE1 treatment the
phenotypical maturation of immature DCs are comparable
to LPS.
Materials and Methods
Cell culture media and recombinant cytokines
In all experiments, we used the complete RPMI-1640
(Sigma Chemical Company; St Louis, MO) medium
supplemented with 10% heat-inactivated fetal bovine serum
(Hyclone laboratories, Logan, UT), 2 mmol/l L-glutamine,
100 U/ml penicillin, 100 µg/ml streptomycin (all from
Gibco-BRL). Recombinant human granulocyte-macrophage
colony-stimulating factor (GM-CSF), recombinant human
interleukin-4 (IL-4), tumor necrosis factor-α (TNF-α),
prostaglandin-E1 and lipopolysaccharide (LPS) were all
purchased from Sigma (Sigma Chemical Company; St Louis,
MO).
Percoll gradient
The 50% Percoll gradient (density 1.064 g/ml) as
described by Almeida25 was used with one modification. First
the isosmotic Percoll solution was prepared with one volu-
me of PBS 10X (137 mM NaCl, 2.6 mM KCl, 8.45 mM
Na2HPO4 and 1.52 mM KH2PO4) and nine volumes of Percoll
(Pharmacia, density 1.130 g/ml), afterwards the 50% Percoll
solution was prepared by mixing 1:1 (v/v) isosmotic Percoll:
PBS1X plus 0.6% ACDA.
Experimental design
DCs were generated from leukocyte-enriched Buffy
coats. The Buffy coat, derived from 500 ml of whole blood
drawn from a healthy volunteer, was supplied by the Blood
Fractionation Laboratory of Regional Blood Center of Ri-
beirão Preto, in compliance with institutional guidelines and
immediately processed.  The leukocyte-enriched Buffy coats
were diluted twice in PBS and the purification of high-
enriched monocyte population was obtained as follows: first
the mononuclear cells were purified by Ficoll-Hypaque
gradient (Pharmacia, density 1.077 g/ml) and centrifuged
at 700 g for 30 min at room temperature. Afterwards, the
MNCs were washed twice with PBS (final volume 20 ml)
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and centrifuged into 20 ml of 50% Percoll solution at 400 g
for 35 min at room temperature. The cells from the interface
were collected, washed twice with PBS and the number of
cells counted. The purity of monocyte population was
evaluated by flow cytometry using an anti-CD14 antibody.
The monocyte (1 x 106/ ml) was subsequently cultured in
24-well plates (Greiner Bio-One Gmblt, Frickenhausen) in
complete RPMI-1640 medium. The following cytokines were
used: 100 ng/ml human granulocyte-macrophage colony-
stimulating factor (GM-CSF) and 50 ng/ml of recombinant
human IL-4 (both from Sigma) for 5 days. One-half of the
culture volume was replaced with fresh medium and
cytokines every 2 days. On day 5, fresh whole medium was
added and four different maturation conditions were tested:
1) TNF-α (10 ng/mL); 2) PGE1 (10
-6 M); 3) TNF-α (10 ng/
ml) plus PGE1 (10
-6 M) and 4) LPS from E. coli (100 ng/
ml). Simultaneously, as a control one-step culture, some
samples were also maintained without adding additional
factors. Following 48 h DCs were harvested and analyzed
by light microscopy and by flow cytometry
Immuno-phenotype analysis
DCs and monocytes were analyzed for expression of
cell surface markers by single-color cytometry. Cells were
harvested after Percoll gradient separation and after
culturing for seven days. A total of 1x106 cells was incubated
for 30 minutes on ice in 2% BSA containing phosphate-
buffered saline (PBS) with the fluorescein isothiocyanate
(FITC) - or phycoerythrin (PE) - conjugated mAb, or with
control irrelevant isotype-matched mAb. The monoclonal
antibodies used were: CD1a, CD80, CD86, CD83, CD40,
CD14 and HLA-DR. HLA class II were analyzed by
fluorescent-labeled Abs against HLA-DR. The stained cells
were washed twice with PBS and fixed with 500 µL of 2%
paraformaldehyde in PBS. Then, cells were kept on ice,
protected from light until flow cytometry analysis. Data
acquisition of 10,000 events was performed using a
FACSortTM flow cytometer (Becton Dickinson, San Jose, CA)
and analysis was performed using Cell-Quest (Becton
Dickinson) software. Dendritic cell regions were
electronically gated according to light and forward scatter
properties to exclude cell debris, dead cells and
contaminating lymphocytes and granulocytes.
Morphologic analysis
Morphologic analysis was performed on an Axioskop
2 plus, Zeiss microscope (Carl Zeiss from Brazil). A total of
2 x 104 cells MNCs cultured for 2 days and DCs cultured
for 7 days were cytocentrifuged using a Cytospin-3 centrifuge
(Shandon Southern Products, Astmoor, UK) on microscope
slides. Then, cytospins were air dried and stained with May-
Grunwald-Giemsa before examining by light microscopy.
Digital pictures were taken with a Zeiss Axioskop 2 plus
(Carl Zeiss) microscope using a x100 NA 1.25 Plan-
Apochromat oil lens and a AxionCam camera (Carl Zeiss).
Digital images were subsequently converted into JPG format
and imported into Adobe Photoshop 4.0 for editing and
printing.
Statistical analysis
Descriptive statistics (arithmetic mean, median, and
standard deviation) was used to describe each group of
data.
Results
Enrichment of monocyte cells after Percoll gradient
and morphological and phenotypical changes after culturing
with GM-CSF plus IL-4
We obtained an enriched-CD14+ cell population after
Percoll gradient centrifugation (Figure 1B). Starting with
approximately 2-8 x 108 peripheral blood mononuclear cells,
Figure 1. Enrichment of monocyte cells after Percoll gradient and downregulation of CD14 expression on immature DCs. Representative flow
cytometric analysis, displaying the phenotype of monocytes cells after Percoll gradient and the absence of CD14 positive cells after seven days in the
presence of GM-CSF and IL-4. (A) FSC vs. SSC profile. The R1 gate corresponds to monocyte population; (B) The collected monocyte cells are on
average 94% CD14 positive (day 0). The black histogram is labeled with control irrelevant mAb and grey histogram is stained with PE-labeled CD14
mAb; (C) The monocyte collected cells were analyzed by two-color cytometry for the expression of CD19 (B lymphocyte) and CD3 (T lymphocyte).
The percentage of cells in each quadrant is listed, and (D) CD14 expression after 7 days in the presence of GM-CSF and IL-3. The immature DCs
are CD14 negative. These data are from one representative experiment of a total of six performed
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we typically ended up with 5-8 x 107
monocytes. Analysis by flow cytometry
showed that the frequency of CD14+
cells was 91% ± 5 and the lymphocyte
contamination with CD3+/CD19+ cells
was low (Figure 1C). Moreover, as
expected, there is a strong decrease in
the expression of CD14 after 7 days in
the presence of GM-CSF plus IL-4 (Fi-
gure 1D) or other culture conditions
(data not shown).
Morphologically, the CD14+ cells
appear with the typical monocyte
morphology, which includes small cells
with a plasma cell-like morphology and
characterized by an eccentric nucleus
and without dendritic projection (Figu-
re 2A). After 7 days in the presence of
GM-CSF plus IL-4 the cells became
larger and few cytoplasmic projections
were observed which is characteristic
of immature DCs (Figure 2B). These
results corroborated with the analysis
by FACS where it was observed that,
compared with the starting cell
population, cells that were cultured
with GM-CSF and IL-4 for 7 days
increased in size and granularity (data
not shown).
The expression of antigens
including HLA DR and CD86 are up-
regulated in the starting cell population
(median value of 81% and 97%,
respectively) while CD1a, CD40, CD80
and CD83 antigens are not detected
(median value between 0.7 and 1.5%).
In the presence of GM-CSF plus IL-4
for 7 days is observed the differentiation
of CD14+ cells into immature DCs as
evaluated by FACS with a significantly
higher expression of CD1a and CD80
(median of 34% and 9%, respectively).
The expression of HLA DR is retained in cells without any
maturating agent while CD86 expression is decreased. Other
phenotypes, including CD40 and CD83 showed a slightly
higher expression compared with the starting cell population
(Figure 3).
Effect of the addition of PGE1 or TNF-α  alone on
phenotypical maturation of immature DCs
In the next series of experiments, we investigated the
effect of PGE1 and TNF-α alone on the phenotypic
maturation of human MoDCs. At day 5 immature MoDCs
were treated with PGE1 or TNF-α stimuli for 48 hours, and
the expression of maturity-related surface markers was
analyzed by flow cytometry. As shown by flow cytometric
analysis, in the presence of TNF-α, or PGE1 alone the
expression of CD1a+ is increased (median value of 82% and
94%, respectively, versus 34%). Related to the expression
of the costimulatory CD80 molecule TNF-α -DCs had a
higher level of expression (median of 40%) when compared
to the levels of CD80 in immature DCs. On the contrary,
CD80 expression could not be efficiently induced by DC
exposed for 48 h to PGE1 alone (median of 26%) when we
compared with immature DCs (Figure 3).
Morphologically, under TNF-α (Figure 2C) or PGE1
Figure 2. Morphological changes after culturing monocyte cells with GM-CSF plus IL-4 and in the
presence or absence of different maturation stimuli. (A) Representative photographs of Wright-
stained cytospins of enriched-CD14+ cells and immature and mature DC cultured for 7 days
under different maturation stimuli: (A) enriched-CD14+ cell population; (B) immature-DCs; (C)
TNF-α -DCs; (D) PGE1-DCs; (E) TNF-α +PGE1-DCs and (F) LPS-DCs.  Magnification 100X.
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(Figure 2D), the cells exhibited an irregular shape and
multiple cytoplasmic processes in many directions that typify
dendritic cells. These results corroborated with the analysis
by FACS where it was observed that the forward – and side
– scatter distribution where higher than those of immature
DCs, suggesting an increase in their size and granularity
properties (data not shown).
The influence of TNF-α or PGE1 on the expression of
other antigens was also observed. As shown in Figure 3
under TNF-α treatment the expressions of HLA DR and
CD86 remained similar to untreated DCs (median of 79%
versus 82%, and 69% versus 61%, respectively), while the
expressions of CD40 and CD83 were higher (median of 27%
versus 12%, and 22% versus 4%, respectively). Similarly,
phenotypic analysis of DCs under PGE1 treatment showed
that the expression of HLA DR remained similar to untreated
DCs (median of 78% versus 82%), and the expression of
CD40 was slightly higher (median of 18% versus 12%).
However, the expression of CD86 was downregulated
(median of 31% versus 61%) and the expression of CD83
could not be stimulated (median of 4%) in both DC cultures,
in the presence or absence of PGE1.
Taken together, these data indicated that TNF-α or
PGE1 can increase the expression of CD1a 2.4 and 2.7
times, respectively, more than DC cultures in the absence
of the maturing agent. However, for other costimulatory
or accessory molecules (CD80, CD86, CD83 and CD40)
TNF-α was more potent in the induction of the expression
than PGE1, suggesting that additional maturation factors
are essential for obtaining efficiently matured DCs.
Figure 3. Greater expression of CD1a and CD80 costimulatory molecule in TNF-α +PGE1-DC and LPS-DC than in TNF-α -DC and PGE1-DC
cultures. CD14+ monocyte-derived DCs were cultured with GM-CSF + IL-4. At day 5 fresh medium was added for 2 days under different stimuli. Cells
were harvested and analyzed at day 7 by FACS after labeling with the isotype controls and indicated mABs. Histograms show profiles of isotype
controls (in grey) and monoclonal Abs (in black). Gates were set to include cells with large FSC and high SSC for DCs in the absence or presence
of different maturating agents. Ten thousand gated events were collected for each analysis. Numbers indicate the percentage of CD expression. Data
shown are representative of 3 to 6 experiments performed. The number of each DC culture conditions performed is indicated above each treatment
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The presence of PGE1 plus TNF-α has similar effect
on phenotypical maturation of immature DCs compared to
LPS
In the third series of experiments, we investigated the
effect of TNF-α in combination with PGE1 on the phenotypic
maturation of human CD14+ derived-DCs (Mo-DCs). At day
5, immature Mo-DCs were treated with TNF-α plus PGE1
stimuli for 48 hours, and the expression of maturity-related
surface markers was analyzed by flow cytometry. Consistent
with a previous work, DCs exposed to TNF-α plus PGE1
have a higher expression of costimulatory and accessory
molecules, CD80 and CD86 than DCs stimulated with TNF-
α or PGE1 alone.
13 Moreover, CD1a showed an elevated
expression. As shown by flow cytometry analysis in the
presence of TNF-α plus PGE1 the expression of CD1a and
CD80 were elevated appreciably when compared with
untreated-DCs (median of 90% and 79%, respectively, versus
34% and 9%). Also, as expected HLA DR and CD86
expression remained high and similar to untreated-DCs
(median of 70% and 81%, respectively, versus 82% and
61%). Therefore, on the contrary to PGE1 treatment where
a decrease of CD86 expression (median of 14%) was
observed the combination TNF-α and PGE1 cooperate to
activate the expression of CD86 (median of 70%).
Surprisingly, TNF-α plus PGE1 treated-DCs did not show
significant increases of CD40 and CD83 expression
compared to untreated or TNF-α-DCs and PGE1-DCs
(median of 28% and 19%, respectively, versus 12% and 4%
for untreated-DCs; versus 27% and 22% for TNF-α-DCs
and versus 12% and 4% for PGE1-DCs). These results can
be explained by DC-culture conditions (see comments on
discussion) or by induction of a specific subset of dendritic
cells.
Morphologically, under TNF-α plus PGE1 treatment
(Figure 2D) the cells exhibited a shape similar to TNF-α
treated-DCs or PGE1 treated-DCs with an irregular shape
and multiple cytoplasmic processes in many directions that
typify dendritic cells.
We next explored the relevance for the observed
enhancement of DC maturation in the presence of TNF-α
plus PGE1. At day 5, immature CD14
+ -derived DCs were
treated with LPS stimuli for 48 hours, and the expression of
maturation-related surface markers was analyzed by flow
cytometry. In LPS-DCs there were no significant differences
in the levels of the expressions of CD1a, CD80, CD86 and
CD83 compared to TNF-α plus PGE1-DCs (median of 81%,
97%, 98% and 21% versus 90%, 79%, 81% and 19%,
respectively, p>0.05). Sequential analysis of other antigens
showed that, the expression of HLA DR and CD40 has a
more pronounced effect in the presence of LPS compared to
TNF-α plus PGE1 treatment (median of 97% and 67% versus
70% and 28%, respectively).
Thus, CD14+-derived DCs treated with TNF-α + PGE1
display phenotypic mature characteristics for CD1a, CD80
and CD86 molecules similar to LPS-treated DCs and higher
than their TNF-α treated-DC or PGE1 treated-DC or
untreated-DC counterparts.
Discussion
A variety of strategies to generate DCs are currently
under investigation and there has been an increasing need
to define the most promising candidate therapies for clinical
studies. At present, most of the preclinical studies use DCs
generated from monocytes isolated after adherence in culture
flasks or from monocytes isolated after depleting lymphocyte
cells with an immune magnetic column. Thus, the enriched-
CD14+ monocyte cell population is differentiated into DCs
in a two-step culture. In the first step GM-CSF and IL-4
promote the differentiation of immature monocyte derived
DCs (iDCs) and in the second step pro-inflammatory factors
induce the terminal maturation of DCs.12-13,21,24,26-28
The studies described here have two proposes, first to
establish a low cost and highly efficient technique to obtain
an enriched-CD14+ monocyte cell population and second to
perform a systematic comparison of the phenotypical
maturation of DCs generated from different maturing agents
that have been used in clinical assays.
The adherence of PBMCs in culture plates for two
hours at 37ºC could be considered the "gold standard" to
isolate monocyte cell populations from progenitor PBMCs.
However, the contamination with lymphocytes may be high.
On the other hand, the second approach, which consists of
using a immune magnetic column, is too expensive for daily
routine. In this study we obtained a CD14+ enriched cell
population by performing Percoll gradient from PBMCs.
The results of FACS analysis of the recovered cells indicate
that 91% ± 5% were CD14+ cells and the content of cells
expressing T and B markers were low. Additionally, these
cells strongly express HLA DR and CD86 and lack
expression of CD1a, CD40, CD80 and CD83.
We further observed that when these cells are
stimulated in vitro with GM-CSF and IL-4 the cells can
survive and enter cell cycles for in vitro DC development
generating a typical iDC phenotype as they acquired CD1a
and CD80 (median of 34% and 9%, respectively) while
loosing CD14 expression. Moreover, the expression of HLA
DR is retained, while CD86 expression decreases.
The question about which is the most efficient cocktail
of cytokines to produce mature DCs has been addressed
previously by several laboratories. In these studies, the
presence of exogenous prostaglandins E2 or E1 enhanced
the TNF-α induced maturation of DCs as analyzed by
morphology, phenotype, ability to stimulate the allogeneic
mixed leukocyte reaction and induction of IL-12
production.13,23,29 Also, the bacterial lipopolysaccharide (LPS)
is known to be an inflammatory stimulus and has been shown
to activate DCs, as well as, whole pathogens or other
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components of microorganisms (e.g. dsRNA, CpG DNA and
toxins,29-30).
However, our study is uniquely extensive in that we
performed a systematic comparison with the yield of all
spectra of DC markers that have been used to address the
DC maturation before and after being exposed to four
different maturating agents, including TNF-α, PGE1,
TNF-α plus PGE1 and LPS.
Consistent with other studies,13,23,29 we show that
TNF-α or PGE1 alone are capable of inducing the
maturation of DCs. Our TNF-α-treated DCs or PGE1-treated
DCs displayed higher expressions of CD1a+ compared with
untreated DCs (median value of 82% and 94%, respectively,
versus 34%) and some differences were found between both
treatments. Analysis of the costimulatory and accessory
molecules CD80, CD86, CD40 and CD83 showed a higher
level after TNF-α treatment compared with PGE1 treatment
(median value of 40%, 78%, 27% and 22% versus and 26%,
13%, 4% and 4%, respectively). However, studies by
Steinbrink et al.13 demonstrated that PGE1-treated DCs are
CD1a- and display higher expressions of CD80, CD86, CD40
and CD83 (81%, 80%, 50% and 55%, respectively). One
possible explanation for this discrepancy is the differences
in the culture conditions chosen. Steinbrink et al.13 favored
X-VIVO 15 + 1% autologous plasma + GM-CSF + IL-4 for
7 days followed by the maturation with PGE1 for 2 days. As
reported by Jonuleit et al.,21 conceivably X-VIVO-cultured
cells show a maturer activation/differentiation stage in
comparison to RMPI-cultured cells, which may need
additional signals, or a longer time in cultures. These authors
also detected lower expressions of CD83 in PGE1-treated
DCs or TNF-α -treated DCs under RPMI conditions, while
Lee et al.23 obtained matured DCs with a higher expression
of this CD marker on day 9 in cultured cells with RPMI
conditions after TNF-α treatment. On the other hand, our
TNF-α -treated DCs are CD1a+, and in agreement with a
previous work this proinflammatory cytokine up-regulates
the MHC class I expression as well as immune proteasome
and TAP molecules at the cell surface of several Melanoma
cell lines31 suggesting that TNF-α treatment is critical for
an efficient immune response.
Moreover, considering that our TNF-α plus PGE1-
treated DCs show a three to five fold higher expression of
CD80, CD40 and CD83 (median of 79%, 28% and 19%,
respectively) as well as CD1a+ remaining highly expressed
(median of 90%) together with the fact that these data are
comparable to DCs generated using LPS in vitro we therefore
suggest that the combination TNF-α  + PGE1 might be useful
for generating ex-vivo DCs for efficient processing and
presentation of antigens and therefore could be used as a
cellular vaccines. LPS is known to be a potent stimulator of
DC maturation32 however it has not been approved for
clinical use because it can induce substantial toxicity. Further
functional evaluation of these mature DCs is warranted.
Also, these three maturating agents, PGE1, TNF-α  and
LPS, mediate their effects by distinct mechanisms: a) PGE2,
a member of the same PGE1 family, mediates its effect on
monocytoid cells via 4 G protein-coupled receptors (EP1, EP2,
EP3 and EP4) two of which mediate their signal through
elevated cyclic adenosine monophosphate (cAMP, 33-34);
b) TNF-α  mediates its effects via CD134 and CD137
receptors; the latter has been shown to be expressed on
follicular dendritic cells35 and c) LPS mediates its effect on
DC activation via TLR4 specific receptors on the surface
of the DC.36 The exact downstream signaling responses
are not clearly understood, but these distinct receptors
suggest distinct targeted genes and may also explain the
differences observed among DCs generated ex-vivo.
Further studies to elucidate the molecular mechanism
involved in the maturation process of DCs is essential not
only to understand the biology of DCs but also to optimize
dendritic cell immunotherapy in humans.
Resumo
Células dendríticas (CDs) são células apresentadoras de antígenos
altamente eficientes para a imunização contra patógenos e
antígenos tumorais. A obtenção de CDs maturis tem sido descrita
por diferentes métodos. Portanto, a escolha do método mais apro-
priado para gerar CDs em cultura de sete dias é pré-requisito
essencial para as estratégias imunoterápicas. Aqui relatamos um
método de obtenção de uma população enriquecida em monócitos
de doadores de sangue e comparamos a maturação das CDs sob
o estímulo de quatro agentes. Uma população de monócitos, com
pureza de 91% ± 5, foi obtida de 15 doadores. A população
monocitária foi mantida em cultura por cinco dias com GM- CSF
e IL - 4. No 5º dia, após diferentes condições de maturação, fo-
ram analisadas as modificações morfológicas  e fenotípicas. Nos-
sos estudos demonstram que o TNF-α ou o PGE1 por si só podem
induzir a expressão de CD1a de 2.4 a 2.7 vezes,  respectivamente,
mais do que culturas de CDs com ausência dos agentes de
maturação. Alternativamente, para com outras moléculas coes-
timuladoras ou acessórias (CD80, CD86, CD83 e CD 40) o
TNF-α foi mais potente na expressão do que o PGE1, embora na
presença de ambos o efeito seja mais pronunciado. A maturação
fenotípica sob TNF-α + PGE1 pode ser comparável ao LPS, con-
cluindo que o TNF-α + PGE1 pode ser útil para geração  ex-vivo
de CDs e útil para protocolos de vacinação celular. Avaliação
funcional das CDs é recomendável. Rev. bras. hematol. hemoter.
2006;28(2):89-96.
Palavras-chave: Células dendríticas; monócitos; Percoll; matu-
ração; imunoterapia.
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